Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Autolus Therapeutics (Nasdaq: AUTL), an early commercial stage biopharmaceutical company focused on programmed T cell therapies, has scheduled its Q1 2025 financial results announcement for May 8, 2025, before US markets open. The company will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss financial performance and provide a business update. Participants must pre-register to receive dial-in details and a personal PIN for the conference call. A simultaneous audio webcast and replay will be available on the company's website events section.
Autolus Therapeutics (Nasdaq: AUTL), un'azienda biofarmaceutica in fase iniziale commerciale specializzata in terapie con cellule T programmate, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 8 maggio 2025, prima dell'apertura dei mercati statunitensi. L'azienda terrà una conference call e una webcast alle 8:30 EDT/13:30 BST per discutere delle performance finanziarie e fornire un aggiornamento sul business. I partecipanti devono registrarsi in anticipo per ricevere i dettagli per la chiamata e un PIN personale. Una webcast audio simultanea e la registrazione saranno disponibili nella sezione eventi del sito web aziendale.
Autolus Therapeutics (Nasdaq: AUTL), una compañía biofarmacéutica en etapa temprana comercial centrada en terapias con células T programadas, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 8 de mayo de 2025, antes de la apertura de los mercados en EE. UU. La empresa realizará una llamada en conferencia y una transmisión en vivo a las 8:30 am EDT/13:30 pm BST para discutir el desempeño financiero y ofrecer una actualización del negocio. Los participantes deben registrarse previamente para recibir los detalles de acceso y un PIN personal para la llamada. Habrá una transmisión de audio simultánea y una repetición disponible en la sección de eventos del sitio web de la compañía.
Autolus Therapeutics (나스닥: AUTL)는 프로그램된 T 세포 치료제에 중점을 둔 초기 상업 단계의 생명공학 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 8일 미국 시장 개장 전으로 예정했습니다. 회사는 오전 8:30 EDT/오후 1:30 BST에 컨퍼런스 콜과 웹캐스트를 개최하여 재무 성과를 논의하고 사업 현황을 업데이트할 예정입니다. 참가자는 사전에 등록하여 전화 접속 정보와 개인 PIN을 받아야 합니다. 동시에 오디오 웹캐스트와 재방송은 회사 웹사이트 이벤트 섹션에서 제공됩니다.
Autolus Therapeutics (Nasdaq : AUTL), une société biopharmaceutique en phase commerciale précoce spécialisée dans les thérapies par cellules T programmées, a prévu l'annonce de ses résultats financiers du premier trimestre 2025 pour le 8 mai 2025, avant l'ouverture des marchés américains. La société organisera une conférence téléphonique et un webinaire à 8h30 EDT/13h30 BST pour discuter des performances financières et fournir une mise à jour commerciale. Les participants doivent s'inscrire à l'avance pour recevoir les détails d'accès et un code PIN personnel pour la conférence téléphonique. Une retransmission audio simultanée et un replay seront disponibles dans la section événements du site web de la société.
Autolus Therapeutics (Nasdaq: AUTL), ein biopharmazeutisches Unternehmen in der frühen kommerziellen Phase, das sich auf programmierte T-Zell-Therapien spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 8. Mai 2025 vor Öffnung der US-Märkte geplant. Das Unternehmen wird um 8:30 Uhr EDT/13:30 Uhr BST eine Telefonkonferenz und einen Webcast abhalten, um die finanzielle Leistung zu besprechen und ein Geschäftsupdate zu geben. Teilnehmer müssen sich vorab registrieren, um Einwahldaten und eine persönliche PIN für die Telefonkonferenz zu erhalten. Ein gleichzeitiger Audiowebcast sowie eine Wiederholung werden im Veranstaltungsbereich der Unternehmenswebsite verfügbar sein.
- None.
- None.
LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its first quarter 2025 financial results and operational highlights before open of US markets on Thursday, May 8, 2025.
Management will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com
Olivia Manser
+44 7780 471 568
o.manser@autolus.com
FAQ
When will Autolus Therapeutics (AUTL) release its Q1 2025 earnings?
How can investors join the Autolus Therapeutics (AUTL) Q1 2025 earnings call?
What time is the Autolus Therapeutics (AUTL) Q1 2025 earnings conference call?
Where can I access the replay of AUTL's Q1 2025 earnings call?
